PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Protagenic Therapeutics, Inc.\new
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.75+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.36M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.4700 (−76.71%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Protagenic Therapeutics, Inc.\new reported revenue of $0 for the twelve months to Dec 31, 2024.
Revenue
$0
TTM Q4 2024
Operating income
-$5.70M
TTM Q4 2024
EPS, diluted
-$15.82
TTM Q4 2024
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.36M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.79
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$5.53M
- EPS, diluted
- -$15.82
- Book value per share
- $0.95
- Diluted shares
- 2M
Eleven years at a glance
Fiscal years 2013 to 2024, USD
Revenue
$0
Operating income
-$5.70M
Net income
-$5.53M
EPS, diluted
-$15.82
Free cash flow
–
Reported period